Trial Profile
A Phase II Trial Of A D1/3-MAGE3-HIS Fusion Protein (NSC-719274) With Adjuvant SBAS02B (NSC-719275) For Patients With Stage IV, M1a or M1b Metastatic Melanoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Zastumotide (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 25 Mar 2008 New trial record.